Tesamorelin Co
Tesamorelin

Evidence

Email me the evidence brief
EvidenceHow long does tesamorelin take to work?Phase 3 data show visceral fat drops start by week 14; full 26-week trials show ~15-18% VAT reduction. Here's the real timeline, by outcome.Updated 2026-07-25Read guide →EvidenceTesamorelin: animal studies vs human clinical evidenceTesamorelin's approval rests on two phase 3 human trials, not animal data. See what's proven, what's extrapolated, and what's still off-label.Updated 2026-07-25Read guide →EvidenceTesamorelin before and after claims: what the trials actually showTesamorelin trials show an 18% average visceral fat drop at 26 weeks in HIV lipodystrophy. Here's what before/after photos leave out, sourced to phase 3 data.Updated 2026-07-25Read guide →EvidenceTesamorelin human studies: what the trials actually showTesamorelin's phase 3 trials cut visceral fat about 18% in HIV lipodystrophy. Here's what the human evidence covers, and where it stops.Updated 2026-07-25Read guide →EvidenceTesamorelin mechanism of action: how it works in the bodyTesamorelin is a GHRH analogue that stimulates the pituitary to release GH in pulses. Here's the receptor biology behind its FDA-approved fat-reduction effect.Updated 2026-07-25Read guide →EvidenceBest tesamorelin peptide: how to actually evaluate oneThere's no "best" tesamorelin brand, only FDA-approved Egrifta and compounded copies. Here's the real evidence, dosing and sourcing checklist before you buy.Updated 2026-07-24Read guide →EvidenceCan women take tesamorelin peptide? what the evidence saysTesamorelin (Egrifta) is FDA-approved for HIV lipodystrophy in adults, not sex-restricted. Here's what the trial data on women actually shows, and what's off-label.Updated 2026-07-24Read guide →EvidenceDoes tesamorelin cause cancer? what the trial data showsTesamorelin's phase 3 trials found no increased cancer signal, but the label carries an IGF-1 caution and cancer patients were excluded. Here's the actual evidence.Updated 2026-07-24Read guide →EvidenceHow long does it take for tesamorelin to work?Trial data shows visceral fat drops start by week 14, with full effect around 26 weeks. Here's the real timeline from the phase 3 tesamorelin studies.Updated 2026-07-24Read guide →EvidenceHow to get tesamorelin: the legal, provider-reviewed routeTesamorelin (Egrifta) is FDA-approved by prescription only, for HIV lipodystrophy. Here's the real path to get it, on-label or off-label, and what to skip.Updated 2026-07-24Read guide →EvidenceTesamorelin: the FDA-approved GHRH analogue, explainedTesamorelin (Egrifta) is FDA-approved for HIV lipodystrophy visceral fat. Phase 3 data, dosing, off-label use, and safety facts, sourced and explained.Updated 2026-07-24Read guide →EvidenceTesamorelin clinical trials: what the phase 3 data actually showsTesamorelin (Egrifta) cut visceral fat about 15-18% in phase 3 HIV trials vs placebo. Here's the trial evidence, what it covers, and what it doesn't.Updated 2026-07-24Read guide →EvidenceTesamorelin in women: what the evidence actually showsEgrifta's phase 3 trials for HIV lipodystrophy enrolled few women. Here's the real female-specific evidence, dosing, and off-label questions answered.Updated 2026-07-24Read guide →EvidenceTesamorelin nasal spray: is there a clinical trial?No approved tesamorelin nasal spray exists. FDA approval covers Egrifta injection only, backed by two phase 3 trials. Here's what the evidence actually shows.Updated 2026-07-24Read guide →EvidenceTesamorelin before and after: what the trial data actually showPhase 3 trials found ~18% visceral fat reduction at 26 weeks with tesamorelin. Here's the real timeline, what changes, and what doesn't.Updated 2026-07-24Read guide →EvidenceTesamorelin peptide stacks: what the evidence actually supportsTesamorelin is FDA-approved alone, for one indication. Stacking with IGF-1 LR3 or other peptides has no phase 3 data. Here's what's actually known.Updated 2026-07-24Read guide →EvidenceTesamorelin results: what the clinical research actually showsTesamorelin cut visceral fat about 18% in phase 3 trials for HIV lipodystrophy. Here's the real evidence, what it doesn't show, and what's still off-label.Updated 2026-07-24Read guide →EvidenceTesamorelin timeline: what to expect week by weekPhase 3 data show visceral fat drops start by week 14 and hold through 26-52 weeks. Here's the realistic tesamorelin timeline, dosed on real trial evidence.Updated 2026-07-24Read guide →EvidenceWhat does tesamorelin actually do in the body?Tesamorelin is FDA-approved for HIV lipodystrophy: phase 3 trials show real visceral fat drops. Here's what it does, and doesn't do, backed by the data.Updated 2026-07-24Read guide →EvidenceWhen to take tesamorelin: timing, cycle length, and dosingTesamorelin is dosed once daily at bedtime by subcutaneous injection. Here's what the phase 3 trials actually say about timing, cycles, and food.Updated 2026-07-24Read guide →
Start provider review